SLAMF7 and plasma cell myeloma: The CARAMBA clinical trial (Phase 1/2; EudraCT No. 2019-001264-30/CARAMBA-1) is evaluating the safety, feasibility, and anti-myeloma efficacy of autologous SLAMF7 CAR T cells [64].